This is a StreetInsider.com Premium Only Page

Conatus Pharmaceuticals (CNAT) – Press Releases

May 27, 2020 08:00 AM Histogen Announces Successful Completion of its Merger with Conatus Pharmaceuticals

May 18, 2020 08:00 AM Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split

May 14, 2020 08:00 AM Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program

May 11, 2020 08:00 AM Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia

May 7, 2020 04:05 PM The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020

May 1, 2020 04:05 PM Conatus Pharmaceuticals Reports First Quarter 2020 Financial Results and Strategic Process Update

Apr 20, 2020 08:00 AM Histogen Announces Investigational Device Exemption Application for HST 002

Apr 15, 2020 08:00 AM Histogen Publishes New Preclinical Data on its HST 003 Orthopedic Program

Apr 6, 2020 08:00 AM Histogen Announces Investigational New Drug Application Amendment for HST 001

Mar 11, 2020 04:45 PM Conatus Pharmaceuticals Reports 2019 Financial Results and Strategic Process Update

Feb 6, 2020 08:00 AM Histogen to Present at BIO CEO & Investor Conference

Jan 30, 2020 08:00 AM Histogen and Allergan Expand Cell Conditioned Media (CCM) Skin Care Partnership

Jan 28, 2020 04:05 PM Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement

Nov 18, 2019 04:05 PM Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member

Nov 5, 2019 04:05 PM Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results

Aug 6, 2019 04:05 PM Conatus Pharmaceuticals Reports Second Quarter 2019 Financial Results and Program Updates

Jun 24, 2019 04:06 PM Conatus to Explore Strategic Alternatives and Implement Restructuring Plan

Jun 24, 2019 04:05 PM Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis

May 2, 2019 04:05 PM Conatus Pharmaceuticals Reports First Quarter 2019 Financial Results and Program Updates

Apr 30, 2019 07:30 AM Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis

Apr 15, 2019 07:30 AM Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

Apr 2, 2019 07:30 AM Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference

Mar 21, 2019 04:05 PM Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis

Mar 13, 2019 09:00 AM Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

Mar 8, 2019 04:05 PM Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates

Mar 1, 2019 07:30 AM Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results

Feb 12, 2019 07:30 AM Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis

Jan 28, 2019 07:30 AM Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials

Dec 5, 2018 07:30 AM Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis

Nov 8, 2018 07:30 AM Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting

Nov 1, 2018 04:05 PM Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates

Oct 25, 2018 07:30 AM Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results

Oct 2, 2018 04:05 PM Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting

Sep 20, 2018 07:30 AM Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension

Sep 19, 2018 07:30 AM Conatus Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 29, 2018 07:30 AM Conatus Pharmaceuticals to Present at BioCentury NewsMakers Conference

Aug 1, 2018 04:05 PM Conatus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Program Updates

Jul 25, 2018 04:05 PM Conatus Pharmaceuticals to Report Second Quarter 2018 Financial Results

Jul 2, 2018 07:30 AM Conatus Pharmaceuticals’ Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis

May 2, 2018 04:05 PM Conatus Pharmaceuticals Reports First Quarter 2018 Financial Results and Program Updates

Apr 30, 2018 07:30 AM Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis and Severe Portal Hypertension

Apr 25, 2018 04:05 PM Conatus Pharmaceuticals to Report First Quarter 2018 Financial Results

Apr 18, 2018 07:30 AM Conatus Pharmaceuticals’ IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo

Apr 9, 2018 07:30 AM Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting

Apr 4, 2018 04:05 PM Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial

Mar 7, 2018 04:05 PM Conatus Pharmaceuticals Reports 2017 Financial Results and Program Updates

Mar 5, 2018 07:30 AM Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts at Upcoming Investor Conferences

Feb 28, 2018 07:30 AM Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results

Feb 12, 2018 07:30 AM Conatus Pharmaceuticals to Host Expert Call on Unmet Need in HCV-SVR Patients

Feb 5, 2018 07:30 AM Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts and Strategic Initiatives at Upcoming Investor Events